Search Results - "MOORE, Dennis F"

Donepezil for Irradiated Brain Tumor Survivors: A Phase III Randomized Placebo-Controlled Clinical Trial by Rapp, Stephen R, Case, L Doug, Peiffer, Ann, Naughton, Michelle M, Chan, Michael D, Stieber, Volker W, Moore, Jr, Dennis F, Falchuk, Steven C, Piephoff, James V, Edenfield, William J, Giguere, Jeffrey K, Loghin, Monica E, Shaw, Edward G

“…Neurotoxic effects of brain irradiation include cognitive impairment in 50% to 90% of patients. Prior studies have suggested that donepezil, a neurotransmitter…”
Get full text

Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study by GALANIS, Evanthia, JAECKLE, Kurt A, RICHON, Victoria M, SCHEITHAUER, Bernd, GIANNINI, Caterina, FLYNN, Patrick J, MOORE, Dennis F, ZWIEBEL, James, BUCKNER, Jan C, MAURER, Matthew J, REID, Joel M, AMES, Matthew M, HARDWICK, James S, REILLY, John F, LOBODA, Andrey, NEBOZHYN, Michael, FANTIN, Valeria R

“…Vorinostat, a histone deacetylase inhibitor, represents a rational therapeutic target in glioblastoma multiforme (GBM). Patients with recurrent GBM who had…”
Get full text

CYP2D6 activity in patients with metastatic breast cancer treated with single agent tamoxifen: results from ECOG-ACRIN E3108 by Stearns, Vered, ONeill, Anne, Schneider, Bryan P, Skaar, Todd C, Liu, Minetta C, Lohrisch, Caroline, Goetz, Matthew P, Vallejos, Carlos S, Sparano, Joseph A, Villa, Diego, Silverman, Paula, Cheema, Puneet S, Moore, Jr, Dennis F, Sledge, Jr, George W

“…In tamoxifen-treated individuals, reduced-function genetic variants in the CYP2D6 gene or inhibition of the enzyme result in low circulating endoxifen…”
Get full text

Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial by Allegra, Carmen J, Yothers, Greg, O'Connell, Michael J, Beart, Robert W, Wozniak, Timothy F, Pitot, Henry C, Shields, Anthony F, Landry, Jerome C, Ryan, David P, Arora, Amit, Evans, Lisa S, Bahary, Nathan, Soori, Gamini, Eakle, Janice F, Robertson, John M, Moore, Jr, Dennis F, Mullane, Michael R, Marchello, Benjamin T, Ward, Patrick J, Sharif, Saima, Roh, Mark S, Wolmark, Norman

“…National Surgical Adjuvant Breast and Bowel Project R-04 was designed to determine whether the oral fluoropyrimidine capecitabine could be substituted for…”
Get full text

Phase III Trial of Fludarabine Plus Cyclophosphamide Compared With Fludarabine for Patients With Previously Untreated Chronic Lymphocytic Leukemia: US Intergroup Trial E2997 by FLINN, Ian W, NEUBERG, Donna S, TALLMAN, Martin S, GREVER, Michael R, DEWALD, Gordon W, BENNETT, John M, PAIETTA, Elisabeth M, HUSSEIN, Mohamad A, APPELBAUM, Frederick R, LARSON, Richard A, MOORE, Dennis F

“…The combination of fludarabine and cyclophosphamide is an effective regimen for patients with chronic lymphocytic leukemia (CLL). However, it may be…”
Get full text

Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial by Algazi, Alain P., Othus, Megan, Daud, Adil I., Lo, Roger S., Mehnert, Janice M., Truong, Thach-Giao, Conry, Robert, Kendra, Kari, Doolittle, Gary C., Clark, Joseph I., Messino, Michael J., Moore, Dennis F., Lao, Christopher, Faller, Bryan A., Govindarajan, Rangaswamy, Harker-Murray, Amy, Dreisbach, Luke, Moon, James, Grossmann, Kenneth F., Ribas, Antoni

“…Preclinical modeling suggests that intermittent BRAF inhibitor therapy may delay acquired resistance when blocking oncogenic BRAF V600 in melanoma 1 , 2 . We…”
Get full text

Capecitabine and Oxaliplatin in the Preoperative Multimodality Treatment of Rectal Cancer: Surgical End Points From National Surgical Adjuvant Breast and Bowel Project Trial R-04 by O'CONNELL, Michael J, COLANGELO, Linda H, PARDA, David S, MOHIUDDIN, Mohammed, ARORA, Amit, EVANS, Lisa S, BAHARY, Nathan, SOORI, Gamini S, EAKLE, Janice, ROBERTSON, John M, MOORE, Dennis F, MULLANE, Michael R, BEART, Robert W, MARCHELLO, Benjamin T, WARD, Patrick J, WOZNIAK, Timothy F, ROH, Mark S, YOTHERS, Greg, WOLMARK, Norman, PETRELLI, Nicholas J, ALLEGRA, Carmen J, SHARIF, Saima, PITOT, Henry C, SHIELDS, Anthony F, LANDRY, Jerome C, RYAN, David P

“…The optimal chemotherapy regimen administered concurrently with preoperative radiation therapy (RT) for patients with rectal cancer is unknown. National…”
Get full text

Phase II Study of Cisplatin Plus Etoposide and Bevacizumab for Previously Untreated, Extensive-Stage Small-Cell Lung Cancer: Eastern Cooperative Oncology Group Study E3501 by Horn, Leora, Dahlberg, Suzanne E, Sandler, Alan B, Dowlati, Afshin, Moore, Dennis F, Murren, John R, Schiller, Joan H

“…To investigate the efficacy and safety of bevacizumab plus cisplatin and etoposide in patients with extensive-stage disease, small-cell lung cancer (ED-SCLC)…”
Get full text

Standard Chemotherapy Compared With High-Dose Chemoradiotherapy for Multiple Myeloma: Final Results of Phase III US Intergroup Trial S9321 by BARLOGIE, Bart, KYLE, Robert A, CROMER, Jeana N, SALMON, Sydney E, DUNE, Brian, CROWLEY, John C, ANDERSON, Kenneth C, GREIPP, Philip R, LAZARUS, Hillard M, HURD, David D, MCCOY, Jason, DAKHIL, Shaker R, LANIER, Keith S, CHAPMAN, Robert A

“…Results of a prospective randomized trial conducted by the Intergroupe Francais du Myélome (IFM 90) indicated that autologous hematopoietic cell-supported…”
Get full text

Clinical Utility of Genomic Recurrence Risk Stratification in Early, Hormone-Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Real-World Experience by Choucair, Khalil, Page, Seth J., Mattar, Bassam I., Dakhil, Christopher S., Nabbout, Nassim H., Deutsch, Jeremy M., Truong, Quoc V., Truong, Phu V., Moore, Dennis F., Cannon, Michael W., Kallail, K. James, Moore, Joseph A., Dakhil, Shaker R., Diab, Radwan, Kamran, Syed, Reddy, Pavan S.

“…RNA-based genomic risk assessment estimates chemotherapy benefit in patients with hormone-receptor positive (HR+)/Human Epidermal Growth Factor 2-negative…”
Get full text

Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232) by Zonder, Jeffrey A., Crowley, John, Hussein, Mohamad A., Bolejack, Vanessa, Moore, Dennis F., Whittenberger, Brock F., Abidi, Muneer H., Durie, Brian G.M., Barlogie, Bart

“…The Southwest Oncology Group conducted a randomized trial comparing lenalidomide (LEN) plus dexamethasone (DEX; n = 97) to placebo (PLC) plus DEX (n = 95) in…”
Get full text

Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02 by Galanis, Evanthia, Anderson, S Keith, Miller, C Ryan, Sarkaria, Jann N, Jaeckle, Kurt, Buckner, Jan C, Ligon, Keith L, Ballman, Karla V, Moore, Jr, Dennis F, Nebozhyn, Michael, Loboda, Andrey, Schiff, David, Ahluwalia, Manmeet Singh, Lee, Eudocia Q, Gerstner, Elizabeth R, Lesser, Glenn J, Prados, Michael, Grossman, Stuart A, Cerhan, Jane, Giannini, Caterina, Wen, Patrick Y

“…Vorinostat, a histone deacetylase (HDAC) inhibitor, has shown radiosensitizing properties in preclinical studies. This open-label, single-arm trial evaluated…”
Get full text

Exceptional Regression of Malignant Pleural Mesothelioma with Pembrolizumab Monotherapy by Hearon, Bernard F., Redelman, Kyle N., Elhomsy, Georges C., Moore, Jr, Dennis F.

“…The lead author with clinical stage I malignant pleural mesothelioma, epithelioid type, highly programmed cell death ligand 1 (PD-L1) positive, and BAP1…”
Get full text

Long-term follow-up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B-cell non-Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC) MC0485 now known as academic and community cancer research united (ACCRU) by Witzig, Thomas E, Johnston, Patrick B, LaPlant, Betsy R, Kurtin, Paul J, Pederson, Levi D, Moore, Jr, Dennis F, Nabbout, Nassim H, Nikcevich, Daniel A, Rowland, Kendrith M, Grothey, Axel

“…Patients with relapsed aggressive non-Hodgkin lymphoma (NHL) are often treated with platinum-based chemoimmunotherapy regimens in preparation for autologous…”
Get full text

Low-Dose, Single-Agent Temsirolimus for Relapsed Mantle Cell Lymphoma : A Phase 2 Trial in the North Central Cancer Treatment Group by ANSELL, Stephen M, INWARDS, David J, ALLMER, Christine, WITZIG, Thomas E, ROWLAND, Kendrith M, FLYNN, Patrick J, MORTON, Roscoe F, MOORE, Dennis F, KAUFMANN, Scott H, GHOBRIAL, Irene, KURTIN, Paul J, MAURER, Matthew

“…The objective of this study was to test a low dose of (25 mg weekly) of the mammalian target of rapamycin kinase inhibitor temsirolimus for patients with…”
Get full text

Phase II trial of R‐CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601 by Till, Brian G., Li, Hongli, Bernstein, Steven H., Fisher, Richard I., Burack, W. Richard, Rimsza, Lisa M., Floyd, Justin D., DaSilva, Marco A., Moore, Dennis F., Pozdnyakova, Olga, Smith, Sonali M., LeBlanc, Michael, Friedberg, Jonathan W.

“…Summary Bortezomib is active in mantle cell lymphoma (MCL), with approval in upfront and relapsed settings. Given inevitable recurrence following induction…”
Get full text

Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Southwest Oncology Group Trial by KELLY, Karen, CROWLEY, John, ISRAEL, Valerie K, LIVINGSTON, Robert B, GANDARA, David R, BUNN, Paul A, PRESANT, Cary A, GREVSTAD, Patra K, MOINPOUR, Carol M, RAMSEY, Scott D, WOZNIAK, Antoinette J, WEISS, Geoffrey R, MOORE, Dennis F

“…This randomized trial was designed to determine whether paclitaxel plus carboplatin (PC) offered a survival advantage over vinorelbine plus cisplatin (VC) for…”
Get full text

Small Lymphocytic Lymphoma Presenting with Hypopituitarism by Moore, Joseph A., MD, Moore, Matthew B., BA, Samaniego, Felipe, MD, Pinnix, Chelsea C., MD, PhD, Moore, Dennis F., MD

Get full text

Nausea and disturbed sleep as predictors of cancer-related fatigue in breast cancer patients: a multicenter NCORP study by Peoples, Anita R., Roscoe, Joseph A., Block, Robert C., Heckler, Charles E., Ryan, Julie L., Mustian, Karen M., Janelsins, Michelle C., Peppone, Luke J., Moore, Dennis F., Coles, Charlotte, Hoelzer, Karen L., Morrow, Gary R., Dozier, Ann M.

“…Purpose Cancer-related fatigue (CRF) is a prevalent and distressing side effect of cancer and its treatment that remains inadequately understood and poorly…”
Get full text

Phase II Study of Tirapazamine, Cisplatin, and Etoposide and Concurrent Thoracic Radiotherapy for Limited-Stage Small-Cell Lung Cancer: SWOG 0222 by LE, Quynh-Thu X, MOON, James, REDMAN, Mary, WILLIAMSON, Stephen K, LARA, Primo N, GOLDBERG, Zelanna, GASPAR, Laurie E, CROWLEY, John J, MOORE, Dennis F, GANDARA, David R

“…A SWOG pilot study (S0004) showed that tirapazamine (TPZ) when combined with concurrent chemoradiotherapy yielded a promising median survival of 22 months in…”
Get full text